Article Text
Statistics from Altmetric.com
Gebhardt in his brief report1 pleads for patient organisations to establish databanks on medical complications. Given the references (for example, an article by Paans, a journalist, entitled “Medical errors to be kept secret”) and the lack of argumentation, there is substantial danger of misinterpretation of the current situation, which in turn may frustrate the process of increased transparency. We would therefore like to respond to this by giving background information and reasons for some of the choices that were made with respect to the registry of complications mentioned by Gebhardt.
First, a distinction needs to be made between an error and an adverse outcome, which are often confused. From Gebhardt’s reference to the journalist’s article which discusses the same registry of adverse outcomes, but with the title referring to errors, both Gebhardt and the journalist think errors and adverse outcomes are the same thing. However, an error refers to the process in which something has gone wrong, a substandard performance, regardless of the outcome. It has been explained by others that such a judgement may have a degree of subjectivity.2 An adverse outcome refers to the outcome which is unwanted but does not necessarily imply that an error has been made. This is why the term “adverse outcomes” is used rather than …
Read the full text or download the PDF:
Other content recommended for you
- Management of recurrent or metastatic thyroid cancer
- Drug treatment of epilepsy in adults
- Adverse drug reactions
- Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol
- Epidemiology of medical error
- A patient-initiated voluntary online survey of adverse medical events: the perspective of 696 injured patients and families
- Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer
- Pharmacogenetics
- Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomised clinical trial: study protocol
- Chronic obstructive pulmonary disease • 8: Non-pharmacological management of COPD